Usama Gergis

Usama Gergis

Auto-generated profile, based on publicly available information

Usama Gergis

Thomas Jefferson University, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMark N. Stein
Mark N. Stein
EDEcaterina E. Dumbrava
Ecaterina E. Dumbrava
BTBenjamin Teply
Benjamin Teply
UGUsama S. Gergis
Usama S. Gergis
MGMARTIN Gutierrez
MARTIN Gutierrez
CBCarlos R. Becerra
Carlos R. Becerra
Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid. Thirty-three patients received BPX-601 with or without rimiducid, 24 patients with mPDAC and 9 with mCRPC. Two dose-limiting toxicities and two treatment-related deaths occurred in the highest-dose mCRPC cohort, after which the study was terminated, without determination of the RP2D. Two mCRPC patients experienced partial responses (one unconfirmed), and 56% of mCRPC patients achieved ≥50% reduction in prostate-specific antigen. BPX-601 cell expansion, long-term persistence in peripheral blood, and tumor infiltration were observed. Rimiducid increased circulating inflammatory cytokines/chemokines consistent with GoCAR-T® cell activation. These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.

1 February 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MNMaxim Norkin
Maxim Norkin
BSBronwen E. Shaw
Bronwen E. Shaw
RBRuta Brazauskas
Ruta Brazauskas
HTHeather R. Tecca
Heather R. Tecca
HLHelen L. Leather
Helen L. Leather
JWJohn R. Wingard
John R. Wingard
We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.

1 January 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SCSaurabh Chhabra
Saurabh Chhabra
YLYing Liu
Ying Liu
MHMichael T. Hemmer
Michael T. Hemmer
LCLuciano Costa
Luciano Costa
JPJoseph A. Pidala
Joseph A. Pidala
BHBetty K. Hamilton
Betty K. Hamilton
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results.

1 April 2014 in Hematology/Oncology and Stem Cell Therapy
Verified
Journal Article
Open access
HHHousam Haddad
Housam Haddad
SSSuchitra Sundaram
Suchitra Sundaram
CMCynthia Magro
Cynthia Magro
UGUsama Gergis
Usama Gergis
Eosinophilic fasciitis (EF) is a rare disease with characteristic clinical and histological features, previously reported to be associated with various hematological and solid malignancies. We report a typical case of eosinophilic fasciitis in a 67-year-old man in association with myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and subsequently bladder cancer. On the two occasions, the eosinophilic fasciitis completely resolved upon successful treatment of the concomitant malignancy. The diagnosis of EF should trigger further evaluation for any associated hematological disorder, which, if adequately treated, can result in the resolution of EF.

30 April 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NANausheen Ahmed
Nausheen Ahmed
FSFang Sun
Fang Sun
CTChristie Teigland
Christie Teigland
KKKarl M. Kilgore
Karl M. Kilgore
IMIman Mohammadi
Iman Mohammadi
UGUsama Gergis
Usama Gergis
Large B-cell lymphoma (LBCL) is the most common type of non-Hodgkin lymphoma. Chimeric antigen receptor T-cell (CAR T) therapy represents a novel treatment with curative potential for relapsed or refractory (R/R) LBCL, but there are access barriers to this innovative therapy that are not well-studied. (1) Assess the impact of geographic factors and social determinants of health (SDOH) on access to treatment with CAR T in a sample of patients with R/R LBCL and ≥ 2 prior lines of treatment (LOT). (2) Compare and contrast patient characteristics, SDOH, and travel time between patients with R/R LBCL who received CAR T and those who did not. An observational, nested case-control study of patients with R/R LBCL, ≥ 2 prior LOT, not in a clinical trial, identified using 100% Medicare Fee-For-Service and national multi-payer claims databases. Patients were linked to near-neighborhood SDOH using 9-digit ZIP-code address. Driving distance and time between residence and nearest CAR T treatment center (TC) was calculated. Patients were stratified based on treatments received upon 3rd LOT initiation (Index Date) or later: 1) received CAR T and 2) did not receive CAR T. Multivariable logistic regression was used to evaluate factors associated with CAR T. 5,011 patients met inclusion criteria, with 628 (12.5%) in the CAR T group. Regression models found the likelihood of receiving CAR T decreased with patient age (OR=0.96, p<.001), and males were 29% more likely to receive CAR T (OR=1.29, p=.02). Likelihood of CAR T increased with Charlson Comorbidity Index (CCI; OR=1.07, P<.001) indicating patients with more comorbidities were more likely to receive CAR T. Black patients were less than half as likely to receive CAR T than White patients (OR=0.44, p=.01). Asian patients did not significantly differ from White patients (OR=1.43, p=.24), and there was a trend for Hispanic patients to have a slightly lower likelihood of CAR T (OR=0.50, p=0.07). Higher household income was associated with receipt of CAR T, with the lowest income group more than 50% less likely to receive CAR T than the highest (OR=0.44, p=.002), and the second lowest income group more than 30% less likely (OR=0.68, p=.02). Finally, likelihood of CAR T therapy was reduced when the driving time to the nearest TC was 121 to 240 minutes (reference group: ≤ 30 minutes; OR=0.64, p=.04). Travel times between 31 and 121 or greater than 240 minutes were not significantly different from ≤ 30 minutes. Payer type was collinear with age and could not be included in the regression analysis, but patients with commercial insurance were 1.5-3 times more likely to receive CAR T than other payers on an unadjusted basis. We identified significant disparities in access to CAR-T related to demographics and SDOH. Patients who were older, female, low income, or Black were less likely to receive CAR-T. The positive association of CCI with CAR T requires further research. Given the promising outcomes of CAR T, there is urgent need to address identified disparities and increase efforts to overcome access barriers.

1 April 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SGSathish Gopalakrishnan
Sathish Gopalakrishnan
ADAnita D'SOuza
Anita D'SOuza
ESEmma Scott
Emma Scott
RFRaphael Fraser
Raphael Fraser
ODOmar Davila
Omar Davila
PHParameswaran Hari
Parameswaran Hari
The revised International Staging System (R-ISS) combines ISS with genetic markers and lactate dehydrogenase and can prognosticate newly diagnosed multiple myeloma (MM). Early relapse (<24 months) after upfront autologous hematopoietic cell transplantation (AHCT) strongly predicts inferior overall survival (OS). We examined the ability of R-ISS in predicting early relapse and its independent prognostic effect on postrelapse survival after an early relapse. Using the Center for International Blood and Marrow Transplant Research database we identified MM patients receiving first AHCT within 18 months after diagnosis with available R-ISS stage at diagnosis (n = 628). Relative risks of relapse/progression, progression-free survival (PFS), and OS were calculated with the R-ISS group as a predictor in multivariate analysis. Among early relapsers, postrelapse survival was tested to identify factors affecting postrelapse OS. The cumulative incidence of early relapse was 23%, 39%, and 50% for R-ISS I, R-ISS II, and R-ISS III, respectively (P < .001). Shorter PFS and OS were seen with higher stage R-ISS. R-ISS was independently predictive for inferior postrelapse OS among early relapsers, as was the presence of ≥3 comorbidities and the use of ≥2 induction chemotherapy lines. R-ISS stage at diagnosis predicts early post-AHCT relapse and independently affects postrelapse survival among early relapsers.